Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23989369 | 0.77 | TSHR (0.44) | CNR2MBOAT4TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL24769074 | 0.76 | CA12 (0.35) | CNR2MBOAT4 | |
| SCHEMBL25464313 | 0.75 | CA12 (0.37) | — | |
| SCHEMBL23991072 | 0.73 | MEN1 (0.35) | CNR2MBOAT4 | |
| SCHEMBL21324946 | 0.71 | CNR2 (0.35) | CNR2 | |
| SCHEMBL25464300 | 0.71 | CA12 (0.41) | — | |
| SCHEMBL25464304 | 0.71 | — | — | |
| SCHEMBL28976853 | 0.69 | MBOAT4 (0.30) | MBOAT4 | |
| SCHEMBL23990479 | 0.68 | L3MBTL1 (0.41) | CNR2TSHRNPSR1SMN1; SMN2 | |
| SCHEMBL25465743 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CNR2 947/4885MBOAT4 4794/4885TSHR 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.